CLINICAL AND SOCIO-ECONOMIC EFFECTIVENESS OF INJECTABLE LONG-TERM FORMS OF ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIA

Since the introduction into practice of Chlorpromazine, a breakthrough in Psychiatry, the range of drugs for schizophrenia has expanded significantly, with atypical antipsychotics being increasingly used in recent times. Despite the advantages of atypical antipsychotics in relation to first-generation antipsychotic drugs, it remains a topic of debate, according to many experts, this is a promising direction of treatment, since this class of drugs has a very pronounced antipsychotic effect in the absence of dose-dependent extrapyramidal and neuroendocrine side effects.